Future cardiologyPub Date : 2024-01-01Epub Date: 2024-07-10DOI: 10.1080/14796678.2024.2343592
Fadi Hage, Ali Hage, Manuel R Cervetti, Michael W A Chu
{"title":"Mitral valve replacement in young patients: review and current challenges.","authors":"Fadi Hage, Ali Hage, Manuel R Cervetti, Michael W A Chu","doi":"10.1080/14796678.2024.2343592","DOIUrl":"10.1080/14796678.2024.2343592","url":null,"abstract":"<p><p>Mitral valve repair is the ideal intervention for mitral valve disease with excellent long-term survival comparable to the age-matched general population. When the mitral valve is not repairable, mechanical prostheses may be associated with improved survival as compared with biological prostheses. Newer mechanical and biological valve prostheses have the potential to improve outcomes following mitral valve replacement in young patients. Patients presenting for mitral valve surgery after failed transcatheter mitral valve-in-valve have high rates of postoperative mortality and morbidity, exceeding those seen with reoperative mitral valve surgery, which poses issues in young patients who have a higher cumulative incidence of reintervention.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"409-417"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-07-23DOI: 10.1080/14796678.2024.2377924
Lei Tian, Su Zhao, Ruiyan Zhang
{"title":"ITIH4 is a predictor for coronary thrombus in coronary arteriography patients.","authors":"Lei Tian, Su Zhao, Ruiyan Zhang","doi":"10.1080/14796678.2024.2377924","DOIUrl":"10.1080/14796678.2024.2377924","url":null,"abstract":"<p><p><b>Aim:</b> To explore potential value of inter-alpha-trypsin inhibitor heavy chain-4 (ITIH4) for coronary artery disease (CAD) diagnosis.<b>Patients & methods:</b> We recruited the patients who received coronary arteriography (CAG) examination. The enzyme-linked immunosorbent assay was used to detect plasma ITIH4.<b>Results:</b> ITIH4 level was lower expression in CAD patients than that in patients of control group, and was negatively correlated with C-reactive protein (CRP). ITIH4 level is no differences between ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial infarction (NSTEMI) patients. However, its expression was significantly correlated with D-Dimer and thrombin time, and the logistic analysis confirmed predictive value of ITIH4 for visible thrombus in coronary.<b>Conclusion:</b> ITIH4 may be a useful biomarker in CAD diagnosis, and to predict visible thrombus in coronary.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"547-554"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-08-19DOI: 10.1080/14796678.2024.2385872
Shaunak Mangeshkar, Pawel Borkowski, Nikita Singh, Panagiotis Zoumpourlis, Maisha Maliha, Sanjana Nagraj, Amrin Kharawala, Robert Faillace
{"title":"Sex differences in Chronic Thromboembolic Pulmonary Hypertension.","authors":"Shaunak Mangeshkar, Pawel Borkowski, Nikita Singh, Panagiotis Zoumpourlis, Maisha Maliha, Sanjana Nagraj, Amrin Kharawala, Robert Faillace","doi":"10.1080/14796678.2024.2385872","DOIUrl":"10.1080/14796678.2024.2385872","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed sequela of acute pulmonary embolism with varied clinical presentation causing significant morbidity among the affected population. There exist important differences in the occurrence, clinical features and diagnosis of CTEPH between men and women, with women carrying a greater predisposition for the disease. Ongoing studies have also pointed out variations among men and women, in the treatment offered and long-term outcomes including mortality. This focused review article highlights important sex-associated differences in multiple aspects of CTEPH including its epidemiology, clinical features, diagnosis, treatment and outcomes as reported in current literature and highlights the need for future research to facilitate a clearer understanding of these differences.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"571-580"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2023-12-19DOI: 10.2217/fca-2023-0095
Saint-Martin Allihien, Sammudeen Ibrahim, Favour Markson, Walter Y Agyeman, Setri Fugar, Onoriode Kesiena
{"title":"The impact of comorbidities and sociodemographic predictors on pneumococcal vaccination coverage in adults with coronary heart disease.","authors":"Saint-Martin Allihien, Sammudeen Ibrahim, Favour Markson, Walter Y Agyeman, Setri Fugar, Onoriode Kesiena","doi":"10.2217/fca-2023-0095","DOIUrl":"10.2217/fca-2023-0095","url":null,"abstract":"<p><p><b>Aim:</b> Coronary heart disease (CHD) increases the risk of adverse outcomes from invasive pneumococcal disease. <b>Methods:</b> Using the 2020 and 2021 data from the national health interview survey, we identified adults with CHD. Chi-square analysis and logistic regression were used to examine factors that influence vaccination status. <b>Results:</b> There were 2675 participants aged 41 and above with CHD. Participants were predominantly white people (82.5%) and males (60.1%). The odds of receiving the pneumococcal vaccine increased with stepwise increase in comorbidities from 1 to 2 and from 2 to 3. Among individuals with ≥2 comorbidities, black people were less likely to be vaccinated compared with white people. <b>Conclusion:</b> Pneumococcal vaccine uptake among adults with CHD is determined by cumulative comorbidities and ethnicity.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"11-19"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-09-27DOI: 10.1080/14796678.2024.2404775
Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab
{"title":"Organizational challenges for partial heart transplantation.","authors":"Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab","doi":"10.1080/14796678.2024.2404775","DOIUrl":"10.1080/14796678.2024.2404775","url":null,"abstract":"<p><p>Partial heart transplantation (PHT) has emerged as a new treatment strategy to correct unrepairable heart valve dysfunction in pediatric patients. PHT selectively replaces the dysfunctional components of the recipient's heart and spares the native ventricles. As a result, the transplant biology of PHTs differs from heart transplants. Notably, donor hearts that are unsuitable for whole heart transplantation can be used, graft preservation can be prolonged and immunosuppression levels can be lowered. These nuances of PHT transplant biology have important implications for organizational aspects of PHT clinical application.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"719-728"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-08-07DOI: 10.1080/14796678.2024.2384239
Stefano De Servi, Antonio Landi
{"title":"A new goal for secondary prevention of cardiovascular diseases: the reduction of neutrophil count.","authors":"Stefano De Servi, Antonio Landi","doi":"10.1080/14796678.2024.2384239","DOIUrl":"10.1080/14796678.2024.2384239","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"517-519"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of right ventricular failure on the outcomes of acute inferior wall myocardial infarction.","authors":"Rishi Shrivastav, Aaqib Malik, Adrija Hajra, Akshay Goel, Avilash Mandal, Sabyasachi Mukhopadhyay, Devesh Rai, Dhrubajyoti Bandyopadhyay","doi":"10.1080/14796678.2024.2378628","DOIUrl":"10.1080/14796678.2024.2378628","url":null,"abstract":"<p><p><b>Aim:</b> Right ventricular failure (RVF) complicates 30-50% of cases with inferior wall myocardial infarctions (IWMI). Large-scale studies exploring the recent trends in morbidity and mortality of IWMI with RVF in the context of improved reperfusion strategies are currently lacking.<b>Materials & methods:</b> The International Classification of Diseases, Tenth Revision, Clinical Modification codes were used to query the National Inpatient Sample of 2018-2019 to yield IWMI admissions and stratified based on presence of RVF. The primary outcome was in-hospital mortality.<b>Results:</b> Out of the 182,485 weighed hospital admissions for IWMI, 1005 patients (0.6%) also had RVF. Patients with both IWMI and RVF had significantly higher mortality than patients with IWMI and no RVF (<i>p</i> < 0.001).<b>Conclusion:</b> RVF in patients with IWMI is an independent predictor of poor outcomes.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"563-569"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-10-22DOI: 10.1080/14796678.2024.2343550
Juan José Gómez Doblas, Xavier García-Moll, Ramón Bover Freire, Carlos González Juanatey, Miren Morillas, Alfonso Valle Muñoz, Carlos Escobar
{"title":"Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting.","authors":"Juan José Gómez Doblas, Xavier García-Moll, Ramón Bover Freire, Carlos González Juanatey, Miren Morillas, Alfonso Valle Muñoz, Carlos Escobar","doi":"10.1080/14796678.2024.2343550","DOIUrl":"10.1080/14796678.2024.2343550","url":null,"abstract":"<p><p><b>Background:</b> Management of oral anticoagulation (OAC) can be challenging, such as in complex cases of nonvalvular atrial fibrillation (NVAF).<b>Materials & methods:</b> A Delphi study comprising two rounds was used for gathering expert opinion through an online questionnaire (83 items grouped in 8 dimensions) on OAC management in specific clinical settings.<b>Results:</b> Consensus was reached for 79 items (95%) in round 1. Experts recommended direct-acting oral anticoagulants (DOACs) for pericardioversion, uninterrupted OAC for catheter ablation, and dual therapy with a DOAC and clopidogrel after percutaneous coronary intervention. They also recommended restarting OAC with a DOAC after an intracranial haemorrhage.<b>Conclusion:</b> The expert-based recommendations obtained may contribute to standardizing and guiding the management of OAC in complex clinical situations in cardiology.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"695-708"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-10-10DOI: 10.1080/14796678.2024.2411167
Arduino A Mangoni, Michael D Wiese, Richard J Woodman, Salvatore Sotgia, Angelo Zinellu, Ciriaco Carru, Julie-Ann Hulin, E Michael Shanahan, Sara Tommasi
{"title":"Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol.","authors":"Arduino A Mangoni, Michael D Wiese, Richard J Woodman, Salvatore Sotgia, Angelo Zinellu, Ciriaco Carru, Julie-Ann Hulin, E Michael Shanahan, Sara Tommasi","doi":"10.1080/14796678.2024.2411167","DOIUrl":"10.1080/14796678.2024.2411167","url":null,"abstract":"<p><p>This article discusses the rationale and design of the study \"Methotrexate, blood pressure, and arterial function in rheumatoid arthritis\". The recognition that immune activation and excess inflammation favor atherosclerosis has stimulated a significant body of research not only to identify new drugs targeting these pathways but also to repurpose (reposition) existing immunomodulatory medications as atheroprotective agents. Observational studies in patients with rheumatoid arthritis have reported that treatment with methotrexate, a traditional disease-modifying antirheumatic drug, is associated with a significantly lower risk of cardiovascular morbidity and mortality when compared with other disease-modifying antirheumatic drugs. One potential mechanism accounting for the reduced cardiovascular risk associated with methotrexate is the lowering effect on arterial blood pressure. However, such effect has only been observed in cross-sectional and observational studies. Given the established role of hypertension as a leading cardiovascular risk factor, these observations justify an intervention comparison study, the focus of this article, investigating the temporal effects of methotrexate on blood pressure and various surrogate markers of atherosclerosis in patients with rheumatoid arthritis. The results of this study might lead to the repurposing of methotrexate for cardiovascular prevention in patients with and without autoimmune disorders.<b>Clinical Trial Registration:</b> NCT03254589 (ClinicalTrials.gov).</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"671-683"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142462757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future cardiologyPub Date : 2024-01-01Epub Date: 2024-10-03DOI: 10.1080/14796678.2024.2404332
Isabel Durães Campos, Ana Rita Ferreira, Armando Abreu, Sérgio Gaião
{"title":"Successful nonsurgical therapeutic management in a case of early mechanical aortic prosthetic thrombosis and coronary embolism after a modified Bentall procedure.","authors":"Isabel Durães Campos, Ana Rita Ferreira, Armando Abreu, Sérgio Gaião","doi":"10.1080/14796678.2024.2404332","DOIUrl":"10.1080/14796678.2024.2404332","url":null,"abstract":"<p><p>Prosthetic valve thrombosis, although rare, is a life-threatening complication of valve replacement surgery. The authors present an atypical case of a modified Bentall procedure with the CarboSeal Valsalva™ conduit complicated by an early mechanical prosthetic aortic valve thrombosis and coronary embolism. The patient was successfully treated with an emergency percutaneous coronary angioplasty and intracoronary thrombus aspiration of the left anterior descending artery, followed by a systemic 10 mg bolus of tissue plasminogen activator followed by ultraslow (25 h) infusion of low-dose (25 mg), while supported with venoarterial extracorporeal membrane oxygenation.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"685-688"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}